tbuckley/cabot-search huggingface dataset:
Angioscope 'sees' chronic pulmonary emboli
Authors: K. Simmons
Journal: JAMA (1984)

A pulmonary fiberoptic angioscope is beginning to be used for direct visualization of chronic pulmonary emboli, which are uncommon and otherwise hard to detect. At this year's meeting of the American College of Chest Physicians held in Chicago, Deborah Shure, MD, of the University of California, San Diego (UCSD), School of Medicine, reported promising preliminary findings using the angioscope that she and co-workers developed in the late 1970s. Although several other groups in the United States are using similar instruments to view the coronary arteries, Shure's use of an angioscope to view the pulmonary arteries is unique. The device, which is 4 mm in diameter and 80 cm long, is guided through a venotomy in the patient's right external jugular vein to the right side of the heart and pulmonary arteries. A xenon light source illuminates structures made visible by a balloon that displaces surrounding blood. The instrument can be
Urinary tract infections in patients with severe renal disease. Treatment with ampicillin and trimethoprim-sulfamethoxazole
Authors: W. M. Bennett
Journal: JAMA (1976)

Twelve patients with severe renal failure and intercurrent urinary tract infections were treated with either ampicillin trihydrate, 500 mg four times a day, or trimethoprim-sulfamethoxazole, two tablets (80 mg trimethoprim, 400 mg sulfamethoxazole) twice a day. All patients achieved bacteriologic cure, including six with proved upper tract infection. Serum levels of all drugs were increased to values above those seen in normal subjects without adverse effects. Urine concentrations of trimethoprim, 28.6μg/ml, and ampicillin, 88.6μg/ml, were well above the minimum inhibitory concentrations of urinary pathogens. Urine sulfamethoxazole concentrations were less than 10μg/ml in four of the six patients treated; however, this did not hamper bacteriologic success. It is concluded that both drugs can be used to treat urinary tract infections in patients with renal functional impairment. (<i>JAMA</i>236:946-948, 1976)
Dynamic Regulation of Receptive Fields and Maps in the Adult Sensory Cortex
Authors: N. Weinberger
Journal: Annual Review of Neuroscience (1995)

The brain's default mode network consists of discrete, bilateral and symmetrical cortical areas, in the medial and lateral parietal, medial prefrontal, and medial and lateral temporal cortices of the human, nonhuman primate, cat, and rodent brains. Its ...Read More
Blood Lead and Coronary Heart Disease Risk among Elderly Men in Zutphen, the Netherlands
Authors: Daan Kromhout
Journal: Environmental Health Perspectives (1988)

Information about blood lead and other coronary heart disease risk factors was collected in 1977 among 152 men aged 57 to 76 years in the town of Zutphen, the Netherlands. Blood lead was determined by atomic absorption spectrometry. The blood lead distribution was skewed to the right. The median blood lead concentration was 167 micrograms/L, and the mean was 183 micrograms/L. Blood lead levels above 300 micrograms/L were present among 8.6% and levels above 400 micrograms/L among 1.3% of the Zutphen men. Blood lead was of borderline significance to cigarette smoking. After both univariate and multivariate analyses, a significant association was found between blood lead and blood pressure. This relation was stronger for systolic than for diastolic blood pressure. Of the 141 elderly men free of coronary heart disease in 1977, 26 developed coronary heart disease between 1977 and 1985. Blood lead was not associated with coronary heart disease incidence in both univariate and multivariate analyses.
Clinical Connections
Journal: Arthritis & Rheumatology (2019)

Semaphorin 4A (Sema4A) is a transmembrane protein belonging to the semaphorin family.In their study, Carvalheiro et al analyzed the potential role of Sema4A in inflammatory and fibrotic processes involved in the pathology of systemic sclerosis (SSc).Sema4A is elevated in plasma, and in the monocytes and CD4+ T cells of SSc patients, and has an apparent dual role in the pathology of the disease.Sema4A induces the expression of Th17 cytokines (interleukin-17 [IL-17], IL-21, and IL-22) in activated CD4+ T cells, promoting the inflammatory activation of dermal fibroblasts.Additionally, Sema4A directly induces in dermal fibroblasts the expression of extracellular matrix components, such as collagen (Col) family members, fibronectin and vimentin, as well as the myofibroblast marker ɑ-smooth muscle actin (ɑ-SMA).Importantly, these effects are abroggated by the neutralization or silencing of the Sema4A receptors plexin D1, plexin B2, and neuropilin-1 (NRP-1).Sema4A thus appears to play a unifying role in the immunopathology of SSc and may be a potentially attractive therapeutic target.
Gunshot Wounds.
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cold ischemia decreases liver regeneration after partial liver transplantation in the rat: A TNF-α/IL-6–dependent mechanism
Authors: N Selzner
Journal: Hepatology (2002)

New strategies of partial liver transplantation such as cadaveric split or living related liver transplantation have been developed to overcome organ shortage. Thus, studies on the ability of small partial grafts to regenerate to normal size while maintaining adequate function have become important. Here, we evaluated the effects of cold preservation on hepatocyte proliferation and function in a novel model of partial liver transplantation in rats. Lewis rats subjected to 70% liver resection (control) were compared with rats that underwent total hepatectomy and 30% partial liver transplantation (recipient). Livers were preserved at 4°C for 30 minutes, 10 hours, or 16 hours in University of Wisconsin solution. Seventy percent liver resection was associated with 100% survival, whereas 30-minute, 10-hour, and 16-hour preservation before 30% transplantation resulted in 80%, 40%, and 20% animal survival, respectively. Prolonged time of cold preservation (10 and 16 hours) was associated with a dramatic decrease of all markers of regeneration (P < .05). Tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6) levels were also significantly decreased in recipient rats compared with the control group. Finally, pretreatment of recipients with recombinant IL-6 (rIL-6) normalized all markers of regeneration and significantly improved survival in the 10-hour group (90% vs. 40%; P < .05). In conclusion, sustained periods of cold preservation significantly impaired TNF-α and IL-6 production, the regenerative ability of the liver, and animal survival. rIL-6 reversed impaired regeneration in the 10-hour cold ischemia group and suggests a primary role of nonparenchymal cells in modulating hepatocyte proliferation in the ischemic liver. (HEPATOLOGY 2002;36:812-818.)
About the Editor
Journal: Liver Cancer (2021)

Consolato M. Sergi, MD, PhD, MPH, FRCPC, FCAP, is a full professor of pathology and adjunct professor of pediatrics at the University of Alberta, Edmonton, Canada. He is also a consultant for Standards and Guidelines in Carcinogenesis of Chemical Compounds&nbsp;published by the World Health Organization/International Agency on Research on Cancer (WHO/IARC monographs), Lyon, France. His research interests include hepatic tumors, metabolic diseases, cholangiopathies, organ transplantation, and gut/bile microbiome using cell lines, animal models, and clinical samples. He identified the role of apoptosis in ductal plate malformation of the liver, characterized sialidosis, and found two new genes, WDR62, which encodes a centrosome-associated protein (Nat Genet 2010) and OTX2, mutations of which can contribute to dysgnathia (J Med Genet 2012). Professor Sergi has published more than 300 research/review articles and several books and book chapters. He has supervised and mentored many PhD students and clinical fellows. He is also on the editorial boards of several scientific journals.
A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti–PD-1) in patients with metastatic castration-resistant prostate cancer.
Authors: Jingsong Zhang, Mark N. Stein, William Kevin Kelly, Che-Kai Tsao, Gerald Steven Falchook, Yuanfang Xu, Frank A. Seebach, Israel Lowy, Kosalai Kal Mohan, Glenn Kroog, Elizabeth Miller
Journal: Journal of Clinical Oncology (2021)

TPS174 Background: Bispecific antibodies (bsAbs) are emerging as a protein-based therapeutic strategy for directing T-cell-mediated cytotoxicity in a tumor antigen-specific manner, typically by binding to both tumor antigen and the CD3 receptor on T-cells. REGN5678 is a human IgG4-based, first-in-class costimulatory bsAb designed to target prostate tumors by bridging prostate specific membrane antigen expressing tumor cells with the costimulatory receptor, CD28, on T-cells, and providing amplified T-cell receptor-CD3 complex-mediated T-cell activation within the tumor through the activation of CD28 signaling. At the tumor site, REGN5678 may synergize with PD-1 inhibitors. In mouse models, REGN5678 in combination with a PD-1 antibody has improved anti-tumor activity compared with either therapy alone (Waite JC et al. Sci Transl Med. 2020:12;549). Methods: This is an open label, Phase I/II, first-in-human study evaluating safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of REGN5678 alone and in combination with cemiplimab in patients with metastatic castration resistant prostate cancer (mCRPC) who progressed after prior therapy (NCT03972657). For inclusion, patients must have received at least two prior lines of systemic therapy (in addition to androgen deprivation therapy) approved for metastatic and/or castration-resistant disease including a second-generation anti-androgen therapy. REGN5678 is administered weekly; cemiplimab (350 mg) is administered once every 3 weeks. During dose escalation, a 3-week safety lead-in of REGN5678 monotherapy will be administered prior to addition of cemiplimab. Study therapies are administered until disease progression, intolerable adverse events, withdrawal of consent, or study withdrawal criterion is met. The primary objectives in dose escalation are to evaluate safety, tolerability, and PK of REGN5678 alone and in combination with cemiplimab. Expansion cohort(s) will be enrolled once a maximum-tolerated REGN5678/cemiplimab dose is reached, or if a recommended Phase 2 dose or doses have been determined. During the expansion phase, the primary objective is to assess clinical activity, as measured by objective response rate of REGN5678 in combination with cemiplimab per modified Prostate Cancer Working Group 3 criteria. At selected sites, prostate-specific membrane antigen PET/CT scans are performed at baseline and select time points on study. This study is currently open to enrollment. Clinical trial information: NCT03972657.
MUCOUS COLITIS.
Authors: ARTHUR D. DUNN
Journal: JAMA (1907)

Mucous colitis is a subject of more than passing interest to the practitioner, to the internist and to the surgeon. It is so involved with constipation, neurasthenia and various surgical conditions that any illumination that can be thrown on the chaos in which the subject is now floundering will be worth the effort. To the general practitioner this disease is of importance, for the prophylaxis lies largely in his hands in the rational treatment of chronic constipation in its early stages and in the proper handling of incipient neurotics. To the internist the disease is of interest because of the diagnostic problems it may present and the numerous therapeutic difficulties to be surmounted before he can accomplish a restoration of health. The analysis of its etiologic and irritative relationship is of prime importance from a curative standpoint. It is not uncommonly closely allied with surgical conditions which aggravate and render
ACUTE INTERNAL HYDROCEPHALUS
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
M. Pasteur
Journal: BMJ (1892)

chemist, and researcher, was celebrated on Tuesday, Decem- ber 27th, by a ceremony-or as our French colleagues say with characteristically lucid exactness-a solemnity which was organised and carried out with every circumstance which could give to it authority, dignified significance, and interest.The chief of the State, M. Carnot, President of the French Republic, officially presided over the ceremony, surrounded by so many of the Ministers that it was elsewhere officially announced that " most of the members of the Cabinet being engaged in the ceremony of the jubilee of M. Pasteur, the Council of Ministers will not meet till to-morrow (Thursday)."The ceremony took place in the grand amphitheatre of the Sorbonne, in the avenues to which
Regional Anesthesia
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Corrections to “Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials”
Authors: S.S. Ramalingam, K. O'Byrne, M. Boyer, T. Mok, P.A. Jänne, H. Zhang, J. Liang, I. Taylor, E.I. Sbar, L. Paz-Ares
Journal: Annals of Oncology (2016)
Viability of Cancer Clinical Research: Patient Accrual, Coverage, and Reimbursement: American Medical Association Council on scientific Affairs
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Viability of Cancer Clinical Research: Patient Accrual, Coverage, and Reimbursement: American Medical Association Council on scientific Affairs Get access JNCI: Journal of the National Cancer Institute, Volume 83, Issue 4, 20 February 1991, Pages 254–259, https://doi.org/10.1093/jnci/83.4.254 Published: 20 February 1991 Article history Received: 24 July 1990 Revision received: 13 November 1990 Accepted: 28 November 1990 Published: 20 February 1991
Variations in methadone treatment practices
Authors: S. Magura
Journal: JAMA (1992)

<h3>In Reply.</h3> —We recently reported that methadone treatment units that have higher average dose levels are more likely to have clients who remain in treatment longer.<sup>1</sup>Dr Magura challenges this finding, but we find his criticisms unwarranted. First, he claims that it is "arbitrary" to add average dose level as a predictor of time in treatment to multiple regression analyses that related characteristics of clients, units, and their environments (as predictors) to treatment practices (as dependent variables). We acknowledge that average dose level is the only measure of treatment practices used in Table 5 both as a dependent and predictor variable. However, we want to make clear our rationale for doing so. First, previous literature suggests that dose level is one of the most important predictors of treatment success (see Dr Cooper's useful review<sup>2</sup>). Thus, given that we had limited degrees of freedom to work with, we elected
Book Review Roentgen Interpretation. A Manual for Students and Practitioners . By George W. Holmes, M.D., Roentgenologist to the Massachusetts General Hospital and Assistant Professor of Roentgenology, Harvard Medical School and Howard E. Ruggles, M.D., Roentgenologist to the University of California Hospital and Clinical Professor of Roentgenology, University of California Medical School. Fourth edition, published 1931. Octavo, 339 pages with 237 engravings. Cloth, $5.00 net.
Journal: New England Journal of Medicine (1931)
Neurotransmitters In Nociceptive Modulatory Circuits
Authors: H. Fields
Journal: Annual Review of Neuroscience (1991)

The brain's default mode network consists of discrete, bilateral and symmetrical cortical areas, in the medial and lateral parietal, medial prefrontal, and medial and lateral temporal cortices of the human, nonhuman primate, cat, and rodent brains. Its ...Read More
Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin
Authors: David Pitcher, Kevin Channer, Michael James, B De Lignieres, J Mas, J Touboul, M Bousser
Journal: BMJ (1986)

Prevention of menstrual migraine by percutaneous oestradiolRoughly 60% of women with migraine relate the periodicity of their headaches to their menstrual cycles, and about a quarter of these women have their headaches exclusively at the time of menstruation.1 2 The physiological withdrawal of oestrogen during the premenstrual phase of the cycle has been suggested to be the precipitating event leading to these menstrual attacks.3We investigated the effect of treatment with percu- taneous oestradiol on menstrual migraine attacks.
Book in Brief
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI- GOIM trial
Authors: E. Martinelli, C. Cardone, T. Troiani, N. Normanno, S. Pisconti, R. Bordonaro, A. Nappi, F. Giuliani, M. Biglietto, C. Barone, A.M. Rachiglio, V. Montesarchio, S. Cinieri, D. Rizzi, A. Febbraro, T.P. Latiano, G. Modoni, G. Colucci, E. Maiello, F. Ciardiello
Journal: Annals of Oncology (2017)
Andre-Victor Cornil (1837-1908)
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal